Get Real Time Here
| Open21.620 | Close20.880 |
| Vol / Avg.2.041M / 2.323M | Mkt Cap2.430B |
| Day Range20.715 - 21.880 | 52 Wk Range3.830 - 21.920 |
CymaBay Therapeutics Stock (NASDAQ:CBAY), Quotes and News Summary
CymaBay Therapeutics Stock (NASDAQ: CBAY) stock price, news, charts, stock research, profile.
| Open21.620 | Close20.880 |
| Vol / Avg.2.041M / 2.323M | Mkt Cap2.430B |
| Day Range20.715 - 21.880 | 52 Wk Range3.830 - 21.920 |
Earnings
see more| Q3 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -0.300 | -0.320 | -0.0200 | ||||
| REV | 0 |
| Q2 2023 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -0.200 | -0.010 | 0.1900 | ||||
| REV | 9.900M | 31.016M | 21.116M |
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|---|---|---|---|---|---|---|
| 2023-11-08 | Cantor Fitzgerald | Kristen Kluska | Maintains | OverweightOverweight | Raises | 23.00 | 24.00 |
| 2023-11-08 | HC Wainwright & Co. | Ed Arce | Maintains | BuyBuy | Raises | 21.00 | 24.00 |
| 2023-11-08 | Raymond James | Steven Seedhouse | Maintains | Strong BuyStrong Buy | Raises | 33.00 | 34.00 |
| 2023-11-06 | Piper Sandler | Yasmeen Rahimi | Maintains | OverweightOverweight | Raises | 19.00 | 33.00 |
Related Companies
| Ticker | Company | Chg % | Mkt Cap |
|---|---|---|---|
| CBAY | CymaBay Therapeutics | -1.56% | 2.4B |
| VRNA | Verona Pharma | 6.95% | 1.2B |
| SUPN | Supernus Pharmaceuticals | -1.32% | 1.5B |
| ANIP | ANI Pharmaceuticals | 0.43% | 999.7M |
| NMRA | Neumora Therapeutics | -1.84% | 1.9B |
How do I buy CymaBay Therapeutics (CBAY) stock?
You can purchase shares of CymaBay Therapeutics (NASDAQ: CBAY) through any online brokerage.
Who are CymaBay Therapeutics's (CBAY) competitors?
Other companies in CymaBay Therapeutics’s space includes: Verona Pharma (NASDAQ:VRNA), Supernus Pharmaceuticals (NASDAQ:SUPN), ANI Pharmaceuticals (NASDAQ:ANIP), Neumora Therapeutics (NASDAQ:NMRA) and Axsome Therapeutics (NASDAQ:AXSM).
What is the target price for CymaBay Therapeutics (CBAY) stock?
The latest price target for CymaBay Therapeutics (NASDAQ: CBAY) was reported by Cantor Fitzgerald on Wednesday, November 8, 2023. The analyst firm set a price target for 24.00 expecting CBAY to rise to within 12 months (a possible 11.99% upside). 36 analyst firms have reported ratings in the last year.
Current Stock Price for CymaBay Therapeutics (CBAY)?
The stock price for CymaBay Therapeutics (NASDAQ: CBAY) is $21.43 last updated December 8, 2023 at 10:48 PM UTC.
Does CymaBay Therapeutics (CBAY) pay a dividend?
There is no dividend information for CymaBay Therapeutics.
When is CymaBay Therapeutics (NASDAQ:CBAY) reporting earnings?
CymaBay Therapeutics’s Q3 earnings are confirmed for Tuesday, November 7, 2023.
Is CymaBay Therapeutics (CBAY) going to split?
There is no upcoming split for CymaBay Therapeutics.
What sector and industry does CymaBay Therapeutics (CBAY) operate in?
CymaBay Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.